Phase I
Roche’s Flatiron Health and the U.S. Food and Drug Administration’s Information Exchange and Data Transformation (INFORMED) Program expanded a two-year-old collaboration agreement.
Karolinska Development’s portfolio company Modus Therapeutics announces that the first cohort has been successfully dosed in its
DTX401 Response in Time to Hypoglycemia and Improved Glucose Control Maintained or Improved in All Three Patients
Combination trial to evaluate safety and anti-tumor activity of agents that target B-cell cancers
For its 2019 list of the top 50 most innovative companies, Fast Company selected 10 from the biotech industry that are having a significant impact on the treatment of patients. The first five are highlighted.
The patients were part of a trial assessing Xencor’s mAb14045, a CD123 x CD3 bispecific antibody molecule being evaluated in patients with relapsed or refractory acute myeloid leukemia.
Four patients with spinal cord injuries will receive nerve cells made from induce pluripotent stem cells in hopes of regaining sensation and mobility lost as a result of the injury.
Combination of antibody drug conjugate and checkpoint inhibitor being evaluated for treatment of relapsed or refractory diffuse large B-cell, mantle cell and follicular lymphomas
Across parts of Europe, Asia and the rest of the globe, pharma and biotech companies have made strides and deals to advance their pipelines and technologies this week.
Shares of Brisbane, Calif.-based Sangamo Therapeutics plunged 30 percent Thursday after the company released preliminary results from a gene-editing trial that investors saw as less than stellar.
PRESS RELEASES